drugset / Trial / NCT00794963
Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
RandomizedParallel-groupOpen-labelTreatment
Summary
Schizophrenia patients treated with clozapine have a high prevalence of obesity-related metabolic syndrome. The condition is often poorly treated and may lead to the emergence of coronary heart disease and type 2 diabetes. The study will investigate whether structured treatment provided at the site of the outpatient psychiatric clinic of metabolic syndrome in this population will decrease the severity of metabolic syndrome as compared with usual care received by these patients in the community.
Timeline
- Start
- 2008-11
- Primary completion
- 2010-05
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orlistat | Small molecule | 60 mg | — |
| Background | Fenofibrate | Small molecule | — | — |
| Background | Irbesartan | Small molecule | — | — |
| Background | Metformin | Small molecule | — | — |
| Background | Pravastatin | Small molecule | — | — |